AZN has been the subject of several other research reports. Deutsche Bank AG reaffirmed a buy rating and issued a GBX 5,800 ($75.71) price objective on shares of AstraZeneca plc in a research note on Friday, July 29th. Jefferies Group reissued a hold rating on shares of AstraZeneca plc in a research report on Monday, June 6th. Berenberg Bank set a GBX 5,550 ($72.44) target price on shares of AstraZeneca plc and gave the stock a buy rating in a research report on Thursday, August 25th. HSBC reissued a hold rating and set a GBX 4,240 ($55.35) target price on shares of AstraZeneca plc in a research report on Friday, June 17th. Finally, Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) target price on shares of AstraZeneca plc and gave the stock a sell rating in a research report on Wednesday, August 10th. Five equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. AstraZeneca plc currently has a consensus rating of Hold and a consensus price target of GBX 4,926.80 ($64.31).
AstraZeneca plc (LON:AZN) opened at 5122.00 on Friday. The company has a 50-day moving average price of GBX 5,023.53 and a 200-day moving average price of GBX 4,390.05. The firm’s market capitalization is GBX 64792.47 billion. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00.
The business also recently disclosed a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were given a dividend of GBX 68.70 ($0.90) per share. This represents a dividend yield of 1.37%. The ex-dividend date was Thursday, August 11th.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.